Study of Nipocalimab in breast milk of healthy nursing women
Treatments studied
This trial tests how much of the drug nipocalimab gets into breast milk. It is for healthy women who are currently breastfeeding their baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy woman between 5 weeks and 24 months after giving birth
- You must be breastfeeding your baby exclusively (or giving no more than 1 bottle of formula per day)
- You cannot have had breast implants, breast reduction, or breast augmentation surgery
- You cannot have an active breast infection (mastitis) at the start of the study
- You cannot have any significant infection in the last 6 weeks
- You must agree to use only lanolin nipple cream if needed during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
This study tests a medicine called nipocalimab for pregnant women whose babies are at risk of a bleeding condition called FNAIT. The medicine may help prevent low platelet counts and serious bleeding in the newborn.
This study tests a new medicine called nipocalimab compared to standard IVIG treatment for pregnant women who are at risk of a serious condition where the mother's antibodies attack the baby's platelets (FNAIT). The goal is to see if nipocalimab can prevent complications like bleeding in the baby.
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.